PMID- 20809989
OWN - NLM
STAT- MEDLINE
DCOM- 20101123
LR  - 20240502
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 9
DP  - 2010 Sep 2
TI  - Increased levels of CRP and MCP-1 are associated with previously unknown abnormal 
      glucose regulation in patients with acute STEMI: a cohort study.
PG  - 47
LID - 10.1186/1475-2840-9-47 [doi]
AB  - BACKGROUND: Inflammation plays an important role in the pathophysiology of both 
      atherosclerosis and type 2 diabetes and some inflammatory markers may also 
      predict the risk of developing type 2 diabetes. The aims of the present study 
      were to assess a potential association between circulating levels of inflammatory 
      markers and hyperglycaemia measured during an acute ST-elevation myocardial 
      infarction (STEMI) in patients without known diabetes, and to determine whether 
      circulating levels of inflammatory markers measured early after an acute STEMI, 
      were associated with the presence of abnormal glucose regulation classified by an 
      oral glucose tolerance test (OGTT) at three-month follow-up in the same cohort. 
      METHODS: Inflammatory markers were measured in fasting blood samples from 201 
      stable patients at a median time of 16.5 hours after a primary percutaneous 
      coronary intervention (PCI). Three months later the patients performed a 
      standardised OGTT. The term abnormal glucose regulation was defined as the sum of 
      the three pathological glucose categories classified according to the WHO 
      criteria (patients with abnormal glucose regulation, n = 50). RESULTS: No 
      association was found between inflammatory markers and hyperglycaemia measured 
      during the acute STEMI. However, the levels of C-reactive protein (CRP) and 
      monocyte chemoattractant protein-1 (MCP-1) measured in-hospital were higher in 
      patients classified three months later as having abnormal compared to normal 
      glucose regulation (p = 0.031 and p = 0.016, respectively). High levels of CRP (>/= 
      75 percentiles (33.13 mg/L)) and MCP-1 (>/= 25 percentiles (190 ug/mL)) were 
      associated with abnormal glucose regulation with an adjusted OR of 3.2 (95% CI 
      1.5, 6.8) and 7.6 (95% CI 1.7, 34.2), respectively. CONCLUSION: Elevated levels 
      of CRP and MCP-1 measured in patients early after an acute STEMI were associated 
      with abnormal glucose regulation classified by an OGTT at three-month follow-up. 
      No significant associations were observed between inflammatory markers and 
      hyperglycaemia measured during the acute STEMI.
FAU - Knudsen, Eva C
AU  - Knudsen EC
AD  - Center for Clinical Heart Research, Oslo University Hospital, Ulleval, Oslo, 
      Norway. evacecilie.knudsen@ulleval.no
FAU - Seljeflot, Ingebjorg
AU  - Seljeflot I
FAU - Michael, Abdelnoor
AU  - Michael A
FAU - Eritsland, Jan
AU  - Eritsland J
FAU - Mangschau, Arild
AU  - Mangschau A
FAU - Muller, Carl
AU  - Muller C
FAU - Arnesen, Harald
AU  - Arnesen H
FAU - Andersen, Geir O
AU  - Andersen GO
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100902
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
RN  - 0 (Biomarkers)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Acute Disease
MH  - Aged
MH  - Biomarkers/blood
MH  - C-Reactive Protein/immunology/*metabolism
MH  - Chemokine CCL2/*blood/immunology
MH  - Cohort Studies
MH  - Electrocardiography
MH  - Female
MH  - Follow-Up Studies
MH  - Glucose Intolerance/diagnosis/*epidemiology/*immunology
MH  - Glucose Tolerance Test
MH  - Humans
MH  - Hyperglycemia/diagnosis/epidemiology/immunology
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/diagnosis/*epidemiology/*immunology
MH  - Prevalence
MH  - Risk Factors
PMC - PMC2940874
EDAT- 2010/09/03 06:00
MHDA- 2010/12/14 06:00
PMCR- 2010/09/02
CRDT- 2010/09/03 06:00
PHST- 2010/07/02 00:00 [received]
PHST- 2010/09/02 00:00 [accepted]
PHST- 2010/09/03 06:00 [entrez]
PHST- 2010/09/03 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
PHST- 2010/09/02 00:00 [pmc-release]
AID - 1475-2840-9-47 [pii]
AID - 10.1186/1475-2840-9-47 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2010 Sep 2;9:47. doi: 10.1186/1475-2840-9-47.